Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safinamide dose-escalation trial for levodopa-induced dyskinesia in Parkinson's disease
2009-017174-20Phase 2Completed
- Sponsor
- Merck Serono
- Start
- Jan 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Parkinson's disease (PD) comparing Safinamide with Placebo (2 arms). Primary endpoint: Unified Dyskinesia Rating Scale total score. Started Jan 2010; status: completed.
02
Drugs
safinamide
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2009-017174-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017174-20.